Transfer of Fresh Versus Frozen/Thawed Embryos in IVF Cycles Where GnRH Agonist is Utilized for Oocyte Maturation.

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2006 by HaEmek Medical Center, Israel.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by:
HaEmek Medical Center, Israel
ClinicalTrials.gov Identifier:
NCT00365027
First received: August 15, 2006
Last updated: NA
Last verified: August 2006
History: No changes posted
  Purpose

It has been suggested that in IVF cycles where GNRH agonist is utilized for final oocyte maturation in patients at risk of ovarian hyperstimulation, pregnancy rates are reduced. We hypothesize that the use of GNRH antagonist reduces pregnancy rates through an effect on the endometrium and not oocyte quality, therefore better results may be obtained by not returning these embryos in a fresh cycle but rather cryopreserving them and returning them to the uterus and a later stage.


Condition Intervention
Ovarian Hyperstimulation Syndrome
Infertility Drugs
Female
Procedure: Delayed embryo transfer

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by HaEmek Medical Center, Israel:

Primary Outcome Measures:
  • Implantation rate per transfer
  • Pregnancy rate per embryo transfer
  • Implantation rate per IVF cycle
  • Pregnancy rate per IVF cycle

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Woman at risk of ovarian hyperstimulation syndrome in IVF cycles for whom GNRH agonist was utilized for final oocyte maturation

Exclusion Criteria:

  • Patient's refusal to participate
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00365027

Contacts
Contact: Ronit Beck Fruchter, Dr 972-4-6495565 beck_r@clalit.org.il

Sponsors and Collaborators
HaEmek Medical Center, Israel
Investigators
Study Chair: Eliezer Shalev HaE'mek medical center
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00365027     History of Changes
Other Study ID Numbers: 5040706
Study First Received: August 15, 2006
Last Updated: August 15, 2006
Health Authority: Israel: Ethics Commission

Keywords provided by HaEmek Medical Center, Israel:
GNRH agonist
ovarian hyperstimulation syndrome
Embryo cryopreservation

Additional relevant MeSH terms:
Infertility
Syndrome
Ovarian Hyperstimulation Syndrome
Genital Diseases, Male
Genital Diseases, Female
Disease
Pathologic Processes
Ovarian Diseases
Adnexal Diseases
Gonadal Disorders
Endocrine System Diseases

ClinicalTrials.gov processed this record on October 01, 2014